4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Virax Biolabs Group Limited (VRAX) operates in the Biotechnology industry and is headquartered in Lanarkshire, United Kingdom with about 26 employees. Its market capitalization is roughly $5 million. In the fiscal year ended 2025-03-31, VRAX reported $0M in revenue and ($6M) in net income.
Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China.
Interactive charts & full statements → Open the VRAX valuation workbench →
| Income statement | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Gross Profit | ($0M) | $0M | $0M | $0M |
| Operating Income (EBIT) | ($6M) | ($6M) | ($6M) | ($2M) |
| Net Income | ($6M) | ($7M) | ($6M) | ($2M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Total Assets | $6M | $6M | $10M | $0M |
| Total Liabilities | $1M | $0M | $1M | $1M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VRAX viewer.
About TickerBase · Data methodology & sources